UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Engaging innate immunity for targeting the epidermal growth factor receptor: Therapeutic options leveraging innate immunity versus adaptive immunity versus inhibition of signaling

Frontiers in oncology, 2022-09, Vol.12, p.892212-892212

2022

Volltextzugriff (PDF)

Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors

mAbs, 2021-01, Vol.13 (1), p.1950264-1950264

2021

Volltextzugriff (PDF)

Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity

mAbs, 2019-07, Vol.11 (5), p.899-918

2019

Volltextzugriff (PDF)

Proteoglycanomics: tools to unravel the biological function of glycosaminoglycans

Proteomics (Weinheim), 2007-08, Vol.7 (16), p.2870-2880

2007

Volltextzugriff (PDF)

CD16A Activation of NK Cells Promotes NK Cell Proliferation and Memory-Like Cytotoxicity against Cancer Cells

Cancer immunology research, 2018-05, Vol.6 (5), p.517-527

2018

Volltextzugriff (PDF)

Abstract 1881: AFM24 is a novel, highly potent, tetravalent bispecific EGFR/CD16A-targeting Innate Cell Engager (ICE®) designed for the treatment of EGFR-positive malignancies

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1881-1881

2021

Volltextzugriff (PDF)

Abstract 5659: AFM24, a bispecific EGFR/CD16A innate cell engager with the potential to overcome resistance to current targeted treatments for EGFR-positive malignancies

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.5659-5659

2020

Volltextzugriff (PDF)

Functionally Defective T Cells After Chemotherapy of B-Cell Malignancies Can Be Activated by the Tetravalent Bispecific CD19/CD3 Antibody AFM11

Journal of immunotherapy (1997), 2019-06, Vol.42 (5), p.180-188

2019

Volltextzugriff (PDF)

Abstract 593: Highly cytotoxic EGFR/CD16A TandAbs specifically recruit NK cells to potently kill various types of solid tumors

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.593-593

2016

Volltextzugriff (PDF)

Abstract 593: Highly cytotoxic EGFRCD16A TandAbs specifically recruit NK cells to potently kill various types of solid tumors

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.593-593

2016

Volltextzugriff (PDF)

EGFR/CD16A tetravalent bispecific antibody AFM24 to engage NK-cells to kill EGFR expressing tumor cells and safety results in cynomolgus monkey studies

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e14001-e14001

2017

Volltextzugriff (PDF)

Preclinical Characterization of AFM26, a Novel B Cell Maturation Antigen (BCMA)-Directed Tetravalent Bispecific Antibody for High Affinity Retargeting of NK Cells Against Myeloma

Blood, 2018-11, Vol.132 (Supplement 1), p.1927-1927

2018

Volltextzugriff (PDF)

Abstract 2471: EGFRvIII T-cell TandAbs are specific and highly potent drug candidates for the treatment of a variety of solid tumors

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.2471-2471

2015

Volltextzugriff (PDF)

Abstract 3753: Identification of antibodies against a novel tumor-associated MHC/peptide-target and generation of highly specific and potent HLA-A02MMP1-003/CD3 TandAbs

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.3753-3753

2017

Volltextzugriff (PDF)

Bacterial expression and functional reconstitution of human heparanase

Carbohydrate research, 2014-05, Vol.389, p.72-77

2014

Volltextzugriff (PDF)

Development of a bispecific tetravalent CD33/CD3 TandAbfor the treatment of AML

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.7071-7071

2015

Volltextzugriff (PDF)

Abstract CT149: A phase 1/2a first-in-human study of AFM24, a CD16A/epidermal growth factor (EGFR) bispecific Innate Cell Engager (ICE®), in patients with locally advanced or metastatic EGFR-expressing solid tumors: Preliminary findings from the dose-escalation phase

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.CT149-CT149

2022

Volltextzugriff (PDF)

Abstract 3521: RECRUIT-TandAb AFM13: Overcoming limitations of monoclonal antibodies in Hodgkin lymphoma

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.3521-3521

2012

Volltextzugriff (PDF)

Abstract 4572: The CD30/CD16A RECRUIT TandAb AFM13 activates patient NK cells resulting in specific tumor cell killing

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.4572-4572

2013

Volltextzugriff (PDF)

Antimycobacterial and H1-antihistaminic activity of 2-substituted piperidine derivatives

Bioorganic & medicinal chemistry, 2008-12, Vol.16 (24), p.10326-10331

2008

Volltextzugriff (PDF)

Antimycobacterial and H sub(1-antihistaminic activity of 2-substituted piperidine derivatives)

Bioorganic & medicinal chemistry, 2008-12, Vol.16 (24), p.10326-10331

2008

Volltextzugriff (PDF)

Antimycobacterial and H 1-antihistaminic activity of 2-substituted piperidine derivatives

Bioorganic & medicinal chemistry, 2008, Vol.16 (24), p.10326-10331

2008

Volltextzugriff (PDF)

Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors

mAbs, 2021, Vol.13 (1)

2021

Volltextzugriff (PDF)

Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity

mAbs, 2019, Vol.11 (5), p.899-918

2019

Volltextzugriff (PDF)

1 – 25 von 26

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(24)
Berichte
(2)

Sprache

Englisch
(26)
Japanisch
(2)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Engaging innate immunity for targeting the epidermal growth factor receptor: Therapeutic options leveraging innate immunity versus adaptive immunity versus inhibition of signaling

Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors

A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myeloma

Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity

Proteoglycanomics: tools to unravel the biological function of glycosaminoglycans

CD16A Activation of NK Cells Promotes NK Cell Proliferation and Memory-Like Cytotoxicity against Cancer Cells

Abstract 1881: AFM24 is a novel, highly potent, tetravalent bispecific EGFR/CD16A-targeting Innate Cell Engager (ICE®) designed for the treatment of EGFR-positive malignancies

Abstract 5659: AFM24, a bispecific EGFR/CD16A innate cell engager with the potential to overcome resistance to current targeted treatments for EGFR-positive malignancies

Functionally Defective T Cells After Chemotherapy of B-Cell Malignancies Can Be Activated by the Tetravalent Bispecific CD19/CD3 Antibody AFM11

Abstract 593: Highly cytotoxic EGFR/CD16A TandAbs specifically recruit NK cells to potently kill various types of solid tumors

Abstract 593: Highly cytotoxic EGFRCD16A TandAbs specifically recruit NK cells to potently kill various types of solid tumors

EGFR/CD16A tetravalent bispecific antibody AFM24 to engage NK-cells to kill EGFR expressing tumor cells and safety results in cynomolgus monkey studies

Preclinical Characterization of AFM26, a Novel B Cell Maturation Antigen (BCMA)-Directed Tetravalent Bispecific Antibody for High Affinity Retargeting of NK Cells Against Myeloma

Abstract 2471: EGFRvIII T-cell TandAbs are specific and highly potent drug candidates for the treatment of a variety of solid tumors

Abstract 3753: Identification of antibodies against a novel tumor-associated MHC/peptide-target and generation of highly specific and potent HLA-A02MMP1-003/CD3 TandAbs

Bacterial expression and functional reconstitution of human heparanase

Development of a bispecific tetravalent CD33/CD3 TandAbfor the treatment of AML

Abstract CT149: A phase 1/2a first-in-human study of AFM24, a CD16A/epidermal growth factor (EGFR) bispecific Innate Cell Engager (ICE®), in patients with locally advanced or metastatic EGFR-expressing solid tumors: Preliminary findings from the dose-escalation phase

Abstract 3521: RECRUIT-TandAb AFM13: Overcoming limitations of monoclonal antibodies in Hodgkin lymphoma

Abstract 4572: The CD30/CD16A RECRUIT TandAb AFM13 activates patient NK cells resulting in specific tumor cell killing

Antimycobacterial and H1-antihistaminic activity of 2-substituted piperidine derivatives

Antimycobacterial and H sub(1-antihistaminic activity of 2-substituted piperidine derivatives)

Antimycobacterial and H 1-antihistaminic activity of 2-substituted piperidine derivatives

Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors

Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity

Suchergebnisse filtern